Complete infarct-related artery revascularization in acute myocardial infarction patients. CORAMI Registry

Zbigniew Siudak1, Blaz Mrevlje2, Bogdan Januś3, Artur Dziewierz4, Tomasz Rakowski5, Jacek Legutko6, Stanisław Bartuś4, Dariusz Dudek1,4

1Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland
2University Heart Center Rostock, Rostock, Germany
3Department of Interventional Cardiology, Municipal Hospital, Tarnow, Poland
42nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland

Abstract

Introduction: There are still limited data on the occurrence of multiple stenotic lesions within the infarct-related artery (IRA) in acute myocardial infarction (MI), and there is no consensus on the optimal treatment of this patient subgroup, which varies between centers and operators.

Aim: To analyse the clinical efficacy of percutaneous coronary intervention (PCI) strategy of culprit lesion only in patients with myocardial infarction.

Material and methods: Patients with acute MI with the presence of at least two significant lesions in the IRA – (1) the target culprit lesion which required immediate stenting (> 50–100% stenosis) and (2) a second distal critical lesion (70–90%) – were included in the registry. Both lesions in the IRA were considered to be independent lesions requiring two separate stent platforms to be covered (no overlap). The decision on the treatment strategy of either complete (CR) or culprit-lesion-only (CLO) revascularization was at the discretion of the operator.

Results: There were altogether 95 patients enrolled in the registry, 63 (66%) in the group with CR of the IRA and 32 (34%) with CLO revascularization, which did not differ in terms of baseline demographics. In-hospital and long-term outcomes were similar between the groups. Stent thrombosis at 1 year occurred in 1.6% in CR and in 6.2% in CLO groups respectively (statistically not significant). There were no patients from the CLO group who had a planned percutaneous coronary intervention (PCI) of the 2nd lesion in the IRA during 1-year observation.

Conclusions: At 1 year the clinical outcome was similar between those with complete and CLO PCI. Complete coverage of significant lesions did not increase the risk of stent thrombosis or need for repeated revascularization in long-term observation.

Key words: myocardial infarction, revascularization, stent, registry.

Introduction

Concomitant significant stenosis in coronary arteries other than the infarct-related artery (IRA) occurs in 40% to 60% of patients undergoing primary percutaneous coronary intervention (PPCI) for ST-elevation myocardial infarction (STEMI) both in historic and recent data [1–7]. Moreover, the presence of multivessel coronary artery disease in the STEMI setting is usually associated with adverse long-term outcome [1, 3, 5–8]. According to the current European Society of Cardiology (ESC) revascularization guidelines, PCI of only culprit vessel should be performed in STEMI, with an exception of cardiogenic shock (IIa), whereas immediate PCI of all lesions during PPCI may only be considered in selected patients (IIb) [9]. Similarly, the mode of revascularization in non-ST elevation myocardial infarction (NSTEMI) should be decided taking into account comorbidities, clinical data and extent of the atherosclerotic disease. There are multiple data from meta-analyses, randomized trials and registries which either support complete revascularization in acute myocardial infarction [10–14] or support a more conservative guideline-recommended approach [15–18]. However, there are still limited data on the occurrence of multiple stenotic lesions within the IRA in a STEMI and NSTEMI setting. At the same time there is no consensus on the optimal treatment of this patient subgroup. The
strategies vary between centers but also PCI operators. Scarce data suggest that "spot" only coverage of stenotic lesions with minimization of stent length might be superior to the “full metal jacket” strategy at least in a group of stable angina patients [19, 20]. It was also confirmed that the length and number of implanted drug eluting stents (DES) is associated with increased risk of stent thrombosis [21, 22].

Aim
The aim of the CORAMI registry was to assess the contemporary treatment strategies in acute myocardial infarction patients with multiple stenotic lesions in the IRA with either complete (CR) or culprit-lesion-only (CLO) revascularization and its influence on long-term outcome.

Material and methods
The CORAMI Registry was first planned as a randomized clinical trial (NCT01218815). The study was launched in Polish and Slovenian sites, but due to difficulties with enrollment the study was terminated. The investigators decided that it would be worth continuing the research, so the CORAMI Registry was started instead.

The CORAMI Registry was a prospective, international (Poland, Slovenia), multicenter (6 sites in Poland, 1 in Slovenia) observational study which was performed in experienced invasive cardiology centers with 24/7 PCI duty with patient enrollment between October 2011 and June 2012.

Patients with STEMI or NSTEMI over 18 years old with the presence of at least two significant lesions in the IRA – (1) the target culprit lesion which required immediate stenting (> 50–100% stenosis) and (2) a second distal critical lesion (70–90%) – were included in the registry. Both lesions in the IRA were considered to be independent lesions requiring two separate stent platforms to be covered (no overlap). The decision on the treatment strategy of either CR or CLO revascularization was at the discretion of the PCI operator. Further pharmacological treatment was according to local standards and best clinical practice. Patient follow-up phone calls and/or ambulatory visits were performed at 12 months after the enrollment.

The primary end-point of this analysis were: overall mortality at 1 year, confirmed stent thrombosis at 12 months according to the Academic Research Consortium (ARC) definition, repeated myocardial infarction at 12 months, urgent target vessel revascularization (TVR) at 12 months and planned TVR (PCI or CABG) at 12 months. Secondary clinical endpoints included: immediate in-hospital angiographic complications (at least one or more of the following: distal embolisation, no-reflow, slow-flow, acute coronary artery occlusion, artery perforation, tamponade, dissection type B and above), urgent in-hospital TVR (PCI and/or CABG), complete radiation dose in mGy.

The CORAMI Registry complied with the Declaration of Helsinki and was approved by the Bioethics Committee at the Jagiellonian University in Krakow, Poland (KBET/140/L/2010 of October 7th, 2010).

Statistical analysis
Data were analyzed according to the established statistical standards. Categorical variables were presented with counts and as percentages and continuous variables as means (± standard deviation). Differences between groups were tested using Fisher’s exact test or Pearson’s \( \chi^2 \) test for categorical variables and the Mann-Whitney \( U \) test for continuous variables. Values of \( p \) less than 0.05 were considered statistically significant. Two-sided tests were applied. All calculations were done with JMP 9.0.0 software by an experienced statistician.

Results
There were altogether 95 patients enrolled in the registry, 63 (66%) in the group with complete revascularization of the IRA and 32 (34%) with CLO revascularization. Baseline demographics and procedural aspects are presented in Table I. The balance of STEMI diagnosis was similar between the groups (CR vs. CLO 73% vs. 84%, \( p = 0.305 \)). In-hospital and long-term outcome as well as adherence to dual antiplatelet therapy are presented in Table II. There were no patients from the CLO group who had a planned PCI of the 2nd lesion in the IRA during 1-year observation.

Discussion
The CORAMI Registry is one of the first studies scheduled to evaluate the impact of complete infarct artery revascularization in patients who are treated with coronary angioplasty with stenting during the acute phase of STEMI and NSTEMI. The incidence of two independent stenotic lesions in the IRA is a rare situation (3% in our population, data not shown) but certainly requires scientific evaluation as there are no clear guidelines on how to intervene, especially in a myocardial infarction setting [9]. Therefore, these decisions are often based on coronary anatomy, patient clinical status and empirical experience of a single PCI operator including thrombolysis in myocardial infarction (TIMI) flow after initial lesion stenting, presence of hemodynamic compromise, location of the distal lesion as well as artery diameter. In the CORAMI study patients with two lesions identified in the IRA were analyzed. The first lesion was treated as the culprit one, which was always stented, and the other was treated with a stent based on the discretion of the PCI operator but had to be less than 90% in diameter stenosis (we did not want to include patients with obvious flow limiting critical lesions > 90%, which should be stented during the index procedure). Our early assumption that most such patients will receive multiple stents to cover all le-
sions turned out to be at least exaggerated. In as many as 34% of STEMI and NSTEMI cases the second distal lesion in the IRA was left without stenting and intended for conservative treatment. During a 12-month follow-up none of the 2nd lesions in the CLO group were scheduled for an elective PCI. Elective PCIs of non-target vessel lesions were performed equally between study groups in follow-up since ca. 2/3 of study patients had multivessel disease diagnosed in baseline angiography.

The benefit of the CLO strategy in STEMI and NSTEMI during in-hospital stay was observed for decreased overall PCI time and lower radiation exposure for the patient, but was only borderline in terms of statistical inference. Even though the mean length of the implanted scaffold in the CR group was ca. 41 mm vs. 21 mm, the immediate PCI outcome in both groups was similar (a rate of TIMI 3 flow). Periprocedural complications as defined by the protocol were rare in both groups. Both during in-hospital and 12-month observation the occurrence of death, stent thrombosis and urgent TVR was more frequently observed in the CLO group, but due to low sample size it was not statistically significant. Thus we need to conclude that in the CORAMI patient sample there was no benefit from complete IRA revascularization at least in terms of occurrence of clinical endpoints in longer observation. Contrary to some reports, there was no excess of stent thrombosis with more stents implanted [21, 22]. It is also interesting to observe that as many as half of patients in the CORAMI registry did not take dual antiplatelet-

### Table I. Baseline characteristics, angiography and PCI

| Variable                              | CR          | CLO         | Value of p |
|---------------------------------------|-------------|-------------|------------|
| No. of patients                       | 66% (63)    | 34% (32)    | –          |
| Age                                   | 66.3 ±11.3  | 69.7 ±11.9  | 0.182      |
| Gender (male)                         | 75% (47)    | 75% (25)    | 0.966      |
| BMI [kg/m²]                           | 27.5 ±3.4   | 27.1 ±3.1   | 0.518      |
| Previous myocardial infarction        | 11% (7)     | 9% (3)      | 0.794      |
| Arterial hypertension                 | 63.5% (40)  | 62.5% (20)  | 0.912      |
| Hyperlipidemia                        | 40% (25)    | 31% (10)    | 0.546      |
| Diabetes mellitus                     | 16% (10)    | 12.5% (4)   | 0.767      |
| Chronic kidney disease                | 3% (2)      | 3% (1)      | 0.989      |
| Previous stroke                       | 1.6% (1)    | 0% (0)      | 0.473      |
| Previous PCI                          | 6% (4)      | 3% (1)      | 0.613      |
| Previous CABG                         | 1.6% (1)    | 0% (0)      | 0.473      |
| Smoking                               | 59% (37)    | 37.5% (12)  | 0.262      |
| Clinical status on admission:         |             |             |            |
| HR                                    | 77.3 ±19.5  | 75.8 ±13.6  | 0.971      |
| SBP                                   | 141 ±26     | 131 ±21     | 0.075      |
| DBP                                   | 81 ±17      | 76 ±11      | 0.042      |
| Number of critically stenosed arteries: |           |             |            |
| 1-vessel disease (IRA only)           | 35% (22)    | 31% (10)    | 0.820      |
| Multivessel disease                   | 65% (41)    | 69% (22)    |            |
| Infarct-related artery (IRA):         |             |             |            |
| LAD                                   | 25% (16)    | 41% (13)    | 0.269      |
| Cx                                    | 8% (5)      | 9% (3)      |            |
| RCA                                   | 67% (42)    | 50% (16)    |            |
| TIMI before PCI:                      |             |             |            |
| 0                                     | 41% (26)    | 56% (18)    | 0.407      |
| 1                                     | 14% (9)     | 16% (5)     |            |
| 2                                     | 21% (13)    | 9% (3)      |            |
| 3                                     | 24% (15)    | 19% (6)     |            |
| Number of stents in IRA:              |             |             |            |
| ≥ 2 stents in IRA                     | 100% (63)   | 0% (0)      | < 0.001    |
| 1 stent in IRA                        | 0% (0)      | 100% (32)   |            |
| No stents in IRA                      | 0% (0)      | 0% (0)      |            |
| Type of stent:                        |             |             |            |
| DES                                   | 44% (28)    | 34% (11)    | 0.385      |
| PCI procedure time [min]              | 35.0 ±21.7  | 26.6 ±18.1  | 0.092      |
| Radiation [mGy]                       | 1406 ±921   | 1171 ±1250  | 0.055      |
| LVEF (%)                              | 53.2 ±10.9  | 51.5 ±12.3  | 0.566      |
| 1st stent diameter [mm]               | 3.2 ±0.4    | 3.2 ±0.4    | 0.824      |
| 1st stent length [mm]                 | 20.5 ±7.3   | 21.1 ±7.4   | 0.737      |
| 2nd stent diameter [mm]               | 3.2 ±0.5    | –           |            |
| 2nd stent length [mm]                 | 20.2 ±7.9   | –           |            |
| TIMI 3 flow after PCI                 | 95% (60)    | 91% (29)    | 0.401      |
| Thrombectomy                          | 25% (16)    | 37.5% (12)  | 0.242      |

### Table II. Primary and secondary clinical endpoints and adherence to DAPT

| Variable                              | CR          | CLO         | Value of p |
|---------------------------------------|-------------|-------------|------------|
| No. of patients                       | 66% (63)    | 34% (32)    | –          |
| 12 months observation:                |             |             |            |
| Death                                 | 6.4% (4)    | 9.4% (3)    | 0.593      |
| Stent thrombosis                      | 1.6% (1)    | 6.2% (2)    | 0.219      |
| Acute MI                              | 1.6% (1)    | 3.1% (1)    | 0.622      |
| Urgent TVR                            | 4.8% (3)    | 9.4% (3)    | 0.383      |
| Planned TVR                           | 0% (0)      | 0% (0)      | –          |
| In-hospital events:                   |             |             |            |
| Death                                 | 1.6% (1)    | 6.2% (2)    | 0.219      |
| Stent thrombosis                      | 1.6% (1)    | 6.2% (2)    | 0.219      |
| Angiographic complications*           | 1.6% (1)    | 5.1% (1)    | 0.622      |
| Urgent TVR (PCI or CABG)              | 1.6% (1)    | 6.2% (2)    | 0.219      |
| DAPT at 12 months:                    |             |             |            |
| Clopidogrel                           | 47.6% (30)  | 34% (11)    | 0.452      |
| Prasugrel                             | 1.6% (1)    | 6.2% (2)    |            |
| Ticagrelol                            | 4.8% (3)    | 6.2% (2)    |            |
| ASA only                              | 46% (29)    | 53.6% (17)  |            |

*Defined as at least one or more of the following: distal embolisation, no-reflow, slow-flow, acute coronary artery occlusion, artery perforation, tamponade, dissection type B and above. DAPT – dual antiplatelet therapy, ASA – acetylsalicylic acid, TVR – target vessel revascularization, PCI – percutaneous coronary intervention, CABG – coronary artery bypass graft, MI – myocardial infarction.
let therapy any longer at 12 months. The CORAMI study raises a number of issues that would ideally be answered in a larger randomized study.

This was a registry study with low sample size, and drawing definite conclusions based on the results of CORAMI should be cautious. There was no independent angiographic core lab evaluation of PCI procedures and procedural complications. The follow-up observation was mainly performed by telephone calls. In addition, the results cannot be applied to patients treated with new stents designs (i.e. mesh covered stents, self-expandable stents) or bioresorbable vascular scaffold implantation during primary PCI for STEMI [23, 24].

Conclusions

Complete infarct-related artery revascularization in acute myocardial infarction was performed in two-thirds of patients in the CORAMI Registry. At 1 year the clinical outcome was similar between those with complete and CLO PCI. Complete coverage of significant lesions did not increase the risk of stent thrombosis or need for repeated revascularization in long-term observation.

Acknowledgments

We would like to thank the Krakow Cardiovascular Research Institute (KCRI) and Kamil Fijorek MSc for professional data management and statistical analysis.

Conflict of interest

The authors declare no conflict of interest.

References

1. Jaski BE, Cohen JD, Trausch J, et al. Outcome of urgent percutaneous transcatheter coronary angioplasty in acute myocardial infarction: comparison of single-vessel versus multivessel coronary artery disease. Am Heart J 1992; 124: 1427-33.
2. Moreno R, Garcia E, Elizaga J, et al. Results of primary angioplasty in patients with multivessel disease. Rev Esp Cardiol 1998; 51: 547-55.
3. Soraja R, Gersh B, Cox D, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J 2007; 28: 1709-16.
4. Xu F, Chen YG, Li JF, et al. Multivessel percutaneous coronary intervention in Chinese patients with acute myocardial infarction and simple nonculprit arteries. Am J Med Sci 2007; 333: 376-80.
5. Hanratty CG, Koyama Y, Rasmussen HH, et al. Exaggeration of nonculprit stenosis severity during acute myocardial infarction: implications for immediate multivessel revascularization. J Am Coll Cardiol 2002; 40: 911-6.
6. van der Schaaf RI, Vis MM, Sjauw KD, et al. Impact of multivessel coronary artery disease on long-term mortality in patients with ST-elevation myocardial infarction is due to the presence of a chronic total occlusion. Am J Cardiol 2006; 98: 1165-9.
7. Dziewierz A, Siudak Z, Rakowski T, et al. Impact of multivessel coronary artery disease and noninfarct-related artery revascularization on outcome of patients with ST-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER Registry). Am J Cardiol 2010; 106: 342-7.
8. Kalarus Z, Lenarczyk R, Kowalczyk J, et al. Importance of complete revascularization in patients with acute myocardial infarction treated with percutaneous coronary intervention. Am Heart J 2007; 153: 304-12.
9. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EuroIntervention 2015; 10: 1024-94.
10. Jo HS, Park JS, Sohn JW, et al. Culprit-lesion-only versus multivessel revascularization using drug-eluting stents in patients with ST-segment elevation myocardial infarction: a Korean acute myocardial infarction registry-based analysis. Korean Circ J 2011; 41: 718-25.
11. Politi L, Sgura F, Rossi R, et al. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. Heart 2010; 96: 662-7.
12. Varani E, Balducelli M, Aquilina M, et al. Single or multivessel percutaneous coronary intervention in ST-elevation myocardial infarction patients. Catheter Cardiovasc Interv 2008; 72: 927-33.
13. Jeger R, Jaguszewski M, Nallamothu BN, et al. Acute multivessel revascularization improves 1-year outcome in ST-elevation myocardial infarction: a nationwide study cohort from the AMIS Plus registry. Int J Cardiol 2014; 172: 76-81.
14. Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013; 369: 1115-23.
15. Manari A, Varani E, Guastaroba P, et al. Long-term outcome in patients with ST segment elevation myocardial infarction and multivessel disease treated with culprit-only, immediate, or staged multivessel percutaneous revascularization strategies: insights from the REAL registry. Catheter Cardiovasc Interv 2014; 84: 912-22.
16. Sethi A, Bahekar A, Bhuriya R, et al. Complete versus culprit only revascularization in acute ST elevation myocardial infarction: a meta-analysis. Catheter Cardiovasc Interv 2011; 77: 163-70.
17. Vlaar PI, Mahmoud KD, Holmes DR Jr, et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol 2011; 58: 692-703.
18. Kornowski R, Mehran R, Dangas G, et al. Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2011; 58: 704-11.
19. Kim S, Yun KH, Kang WC, et al. Comparison of full lesion coverage versus spot drug-eluting stent implantation for coronary artery stenoses. Yonsei Med J 2014; 55: 584-91.
20. Katritsis DG, Korovesis S, Tzanelaидou E, et al. Comparison of long versus short (“spot”) drug-eluting stenting for long coronary stenoses. Am J Cardiol 2009; 104: 786-90.
21. Chieffo A, Bonizzoni E, Orlic D, et al. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation 2004; 109: 2732-6.

22. Pinto Slottow TL, Steinberg DH, Roy PK, et al. Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol 2008; 102: 298-303.

23. Dudek D, Dziewierz A, Kleczynski P, et al. Long-term follow-up of mesh-covered stent implantation in patients with ST-segment elevation myocardial infarction. Kardiol Pol 2014; 72: 140-5.

24. Dudek D, Rzeszutko L, Zasada W, et al. Biodegradable vascular scaffolds in patients with acute coronary syndromes: POLAR ACS study. Pol Arch Med Wewn 2014; 124: 669-77.